[ad_1]
Vancouver, British Columbia, June 19, 2021 (Global News Agency) – Core One Lab Company (Full education:Fresh), (OTC transactions:CLABF), (Frankfurt: LD62, WKN: A2P8K3) (“the company“) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akame“) Began to develop the next generation of psychedelic drug formulations to reduce nerve damage caused by ischemic strokes.
Akome is a new generation psychedelic drug formulation used to reduce nerve damage caused by ischemic stroke, also known as AKO001, composed of the psychedelic compound N, N-dimethyltryptamine (DMT) and a substance specific plant bioactive. individual immediately after an ischemic stroke, it acts in a regenerative and relieved manner. A provisional combined patent application for AKO001 has been submitted to the United States Patent and Trademark Office (USPTO) under application number 63147343.
Ischemia is a condition in which blood vessels are blocked and blood flow stops or decreases. When the blood flow to a certain part of the body decreases, that part of the body cannot get enough oxygen. Most strokes are ischemic in nature, the blood flow in the arteries that supply the brain with oxygen-rich blood is blocked, and brain cells begin to die. Ischemic stroke is the third leading cause of death in the world and the leading cause of disability in adults worldwide. 1The World Health Organization estimates that 17.9 million people worldwide die of stroke each year.
The plant bioactive substances specially selected by Akome and DMT are an ideal combination of compounds to reduce nerve damage caused by ischemic strokes. This…
The full story on Benzinga.com
[ad_2]
Pictures Credit